Michael L O'Byrne1, Jennifer A Faerber2, Hannah Katcoff2, Jing Huang3, Jonathan B Edelson4, David M Finkelstein5, Bethan A Lemley5, Christopher M Janson5, Catherine M Avitabile5, Andrew C Glatz6, David J Goldberg5. 1. Division of Cardiology, Department of Pediatrics, the Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Center for Pediatric Clinical Effectiveness at The Children's Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute and Cardiovascular Outcomes, Quality, and Evaluative Research Center, University of Pennsylvania, Philadelphia, PA. Electronic address: obyrnem@chop.edu. 2. Department of Biomedical and Health Informatics, Data Science and Biostatistics Unit, The Children's Hospital of Philadelphia, Philadelphia, PA. 3. Division of Cardiology, Department of Pediatrics, the Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Department of Biostatistics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 4. Division of Cardiology, Department of Pediatrics, the Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Leonard Davis Institute and Cardiovascular Outcomes, Quality, and Evaluative Research Center, University of Pennsylvania, Philadelphia, PA. 5. Division of Cardiology, Department of Pediatrics, the Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 6. Division of Cardiology, Department of Pediatrics, the Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Center for Pediatric Clinical Effectiveness at The Children's Hospital of Philadelphia, Philadelphia, PA.
Abstract
BACKGROUND: Survivors of Fontan palliation are at life-long risk of thrombosis, arrhythmia, and circulatory failure. To our knowledge, no studies have evaluated current United States pharmaceutical prescription practice in this population. METHODS: A retrospective observational study evaluating the prevalent use of prescription medications in children and adolescents with hypoplastic left heart syndrome or tricuspid atresia after Fontan completion (identified using ICD9/10 codes) was performed using data contained in the MarketScan Commercial and Medicaid databases for the years 2013 through 2018. Cardiac pharmaceuticals were divided by class. Anticoagulant agents other than platelet inhibitors, which are not uniformly a prescription medication, were also studied. Associations between increasing age and the likelihood of a filled prescription for each class of drug were evaluated. Annualized retail costs of pharmaceutical regimens were calculated. RESULTS: A cohort of 4,056 subjects (median age 12 years [interquartile range: 8-16], 61% male, 60% commercial insurance) was identified. Of the cohort, 50% received no prescription medications. Angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) (38%), diuretics (15%), and mineralocorticoid receptor antagonists (8%) were prescribed with the highest frequency. Pulmonary vasodilators were received by 6% of subjects. Older age was associated with increased likelihood of filled prescriptions for anticoagulants (P = .008), antiarrhythmic agents, digoxin, ACEi/ARB, and beta blockers (each P < .0001), but also lower likelihood of filled prescriptions for pulmonary vasodilators, conventional diuretics (both P < .0001), and mineralocorticoid receptor antagonists (P = .02). CONCLUSIONS: Pharmaceuticals typically used to treat heart failure and pulmonary hypertension are the most commonly prescribed medications following Fontan palliation. While the likelihood of treatment with a particular class of medication is associated with the age of the patient, determining the optimal regimen for individual patients and the population at large is an important knowledge gap for future research.
BACKGROUND: Survivors of Fontan palliation are at life-long risk of thrombosis, arrhythmia, and circulatory failure. To our knowledge, no studies have evaluated current United States pharmaceutical prescription practice in this population. METHODS: A retrospective observational study evaluating the prevalent use of prescription medications in children and adolescents with hypoplastic left heart syndrome or tricuspid atresia after Fontan completion (identified using ICD9/10 codes) was performed using data contained in the MarketScan Commercial and Medicaid databases for the years 2013 through 2018. Cardiac pharmaceuticals were divided by class. Anticoagulant agents other than platelet inhibitors, which are not uniformly a prescription medication, were also studied. Associations between increasing age and the likelihood of a filled prescription for each class of drug were evaluated. Annualized retail costs of pharmaceutical regimens were calculated. RESULTS: A cohort of 4,056 subjects (median age 12 years [interquartile range: 8-16], 61% male, 60% commercial insurance) was identified. Of the cohort, 50% received no prescription medications. Angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) (38%), diuretics (15%), and mineralocorticoid receptor antagonists (8%) were prescribed with the highest frequency. Pulmonary vasodilators were received by 6% of subjects. Older age was associated with increased likelihood of filled prescriptions for anticoagulants (P = .008), antiarrhythmic agents, digoxin, ACEi/ARB, and beta blockers (each P < .0001), but also lower likelihood of filled prescriptions for pulmonary vasodilators, conventional diuretics (both P < .0001), and mineralocorticoid receptor antagonists (P = .02). CONCLUSIONS: Pharmaceuticals typically used to treat heart failure and pulmonary hypertension are the most commonly prescribed medications following Fontan palliation. While the likelihood of treatment with a particular class of medication is associated with the age of the patient, determining the optimal regimen for individual patients and the population at large is an important knowledge gap for future research.
Authors: Tarek Alsaied; Said Alsidawi; Catherine C Allen; Jenna Faircloth; Joseph S Palumbo; Gruschen R Veldtman Journal: Heart Date: 2015-08-28 Impact factor: 5.994
Authors: Nathalia Jimenez; Alex Quistberg; Monica S Vavilala; Kenneth M Jaffe; Frederick P Rivara Journal: Pediatrics Date: 2017-02-03 Impact factor: 7.124
Authors: Kiona Y Allen; Tacy E Downing; Andrew C Glatz; Lindsay S Rogers; Chitra Ravishankar; Jack Rychik; Stephanie Fuller; Lisa M Montenegro; James M Steven; Thomas L Spray; Susan C Nicolson; James William Gaynor; David J Goldberg Journal: Am J Cardiol Date: 2017-03-16 Impact factor: 2.778
Authors: Michael L O'Byrne; Andrew C Glatz; Lihai Song; Heather M Griffis; Marisa E Millenson; Matthew J Gillespie; Yoav Dori; Aaron G DeWitt; Christopher E Mascio; Jonathan J Rome Journal: Circulation Date: 2018-11-06 Impact factor: 29.690
Authors: Michael L O'Byrne; Russell T Shinohara; Elena K Grant; Joshua P Kanter; Matthew J Gillespie; Yoav Dori; Jonathan J Rome; Andrew C Glatz Journal: Am Heart J Date: 2017-07-19 Impact factor: 4.749
Authors: David J Goldberg; Benjamin French; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik Journal: Circulation Date: 2011-03-07 Impact factor: 29.690
Authors: Thomas G Wilson; Ajay J Iyengar; David S Winlaw; Robert G Weintraub; Gavin R Wheaton; Thomas L Gentles; Julian Ayer; Leeanne E Grigg; Robert N Justo; Dorothy J Radford; Andrew Bullock; David S Celermajer; Kim Dalziel; Chris Schilling; Yves d'Udekem Journal: Int J Cardiol Date: 2016-02-18 Impact factor: 4.164
Authors: Eyal Leshem; Rebecca E Moritz; Aaron T Curns; Fangjun Zhou; Jacqueline E Tate; Benjamin A Lopman; Umesh D Parashar Journal: Pediatrics Date: 2014-06-09 Impact factor: 7.124
Authors: Michael L O'Byrne; Lihai Song; Jing Huang; David J Goldberg; Monique M Gardner; Chitra Ravishankar; Jonathan J Rome; Andrew C Glatz Journal: Pediatr Cardiol Date: 2021-02-02 Impact factor: 1.655
Authors: Anushree Agarwal; Robert Thombley; Craig S Broberg; Ian S Harris; Elyse Foster; Vaikom S Mahadevan; Anitha John; Eric Vittinghoff; Greg M Marcus; R Adams Dudley Journal: J Am Heart Assoc Date: 2019-10-02 Impact factor: 5.501
Authors: Justin H Berger; Jennifer A Faerber; Feiyan Chen; Kimberly Y Lin; Julie A Brothers; Michael L O'Byrne Journal: J Am Heart Assoc Date: 2022-03-18 Impact factor: 6.106